| Jul 17 |
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
|
| Jul 16 |
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
|
| Jul 15 |
(HUMA) - Analyzing Humacyte's Short Interest
|
| Jul 9 |
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
|
| Jul 2 |
While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership
|
| Jul 1 |
Humacyte stock rallies 19% on FDA RMAT designation
|
| Jul 1 |
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
|
| Jun 25 |
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
|
| Jun 17 |
Tommy Tuberville Sells Several Large Stock Positions, Makes New Buys: Here's What The US Senator Is Betting On Now
|
| Jun 17 |
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
|
